Numbness and tingling in the hands can be unsettling, especially if it occurs frequently. It might feel like tingling, pins ...

HIV/AIDS-associated polyneuropathy, and autoimmune polyneuropathy), treatment (drugs and other treatments), and distribution channel (hospitals, clinics, retail pharmacies, and online pharmacies ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating yesterday.Stay Ahead of the ...

JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Rockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global Polyneuropathy Treatment Market is set to reach US$ 2.05 ...

To achieve the goals set out in its 'Vision 2030', argenx has set the following priorities for 2025: Expand the global VYVGART opportunity by reaching more patients broadly across MG, CIDP and ITP ...

Vyvdura receives Japanese regulatory approval for adults with chronic inflammatory demyelinating polyneuropathy: Rotterdam, the Netherlands Monday, December 30, 2024, 1 ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Argenx Se (ARGX – Research Report). The associated price ...

The review highlights the discovery of autoimmune nodopathies, a new category of neurological disorders distinct from traditional Guillain-Barré syndrome and chronic inflammatory demyelinating ...